Covovax Explained: Adding another weapon to India's Covid arsenal

As the Omicron variant spreads rapidly, India is ramping up it's arsenal against Covid-19. Here is what you need to know about Serum Institute manufactured Covovax-:

Also watch | Covid-19: India clears 2 new vaccines - Corbevax & Covovax - and one oral pill

• It is a protein-based Covid-19 vaccine developed by Novavax in the US
  In August Novavax had given SII the licence to manufacture and supply the vaccine
• The WHO has already cleared it and it has an Emergency Use Authorization (EUA)
• Covovax has reported an efficacy of over 89% during it's clinical trial.
• Covovax targets the spike protein on the surface of the SARS-CoV-2 coronavirus
• Once a person is given a shot of this vaccine, the body is expected to recognise these copies of the spike proteins as a foreign substance and build immunity against them.
• Different from Covishield which uses a separate virus to carry the weakened spike protein to trigger an immunity response